https://scholars.lib.ntu.edu.tw/handle/123456789/579419
標題: | Fusidic acid for the treatment of bone and joint infections caused by meticillin-resistant Staphylococcus aureus | 作者: | Wang J.-L. Tang H.-J. Hsieh P.-H. Chiu F.-Y. Chen Y.-H. Chang M.-C. Huang C.-T. Liu C.-P. Lau Y.-J. Hwang K.-P. Ko W.-C. CHEN-TI WANG Liu C.-Y. Liu C.-L. PO-REN HSUEH |
公開日期: | 2012 | 出版社: | Elsevier B.V. | 卷: | 40 | 期: | 2 | 起(迄)頁: | 103-107 | 來源出版物: | International Journal of Antimicrobial Agents | 摘要: | There is a lack of surveillance data on resistance to fusidic acid (FA) in Asia, and no reviews of FA usage for the treatment of orthopaedic infections have been conducted since the year 2000. In this study, we present a systemic literature review of FA resistance in Asia and the clinical use of FA for the treatment of bone and joint infections (BJIs). The in vitro activity of FA against meticillin-resistant Staphylococcus aureus (MRSA) isolates remains good, with low (<10%) resistance rates in most Asian countries. FA in Asia appears to be a better oral anti-MRSA agent than trimethoprim/sulfamethoxazole and clindamycin. More than 80 cases of FA use for BJI have been reported since 2000 and the recurrence or failure rate is <10%. There is much evidence supporting the use of FA in combination with other antibiotics (e.g. rifampicin) as an oral treatment following intravenous glycopeptide treatment for BJIs. ? 2012 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84864286748&doi=10.1016%2fj.ijantimicag.2012.03.010&partnerID=40&md5=888310898a744c29ce2dc22df3c346d0 https://scholars.lib.ntu.edu.tw/handle/123456789/579419 |
ISSN: | 0924-8579 | DOI: | 10.1016/j.ijantimicag.2012.03.010 | SDG/關鍵字: | chloramphenicol; ciprofloxacin; clindamycin; cotrimoxazole; doxycycline; fosfomycin; fusidate sodium; fusidic acid; glycopeptide; linezolid; minocycline; pristinamycin; rifampicin; teicoplanin; vancomycin; antibacterial activity; antibiotic resistance; Asia; bacterial arthritis; bone and joint infections; drug excretion; drug metabolism; drug potentiation; drug treatment failure; endocarditis; Europe; human; in vitro study; infectious arthritis; loading drug dose; methicillin resistant Staphylococcus aureus; nonhuman; North America; osteomyelitis; priority journal; prosthetic joint infection; recommended drug dose; recurrent disease; review; Staphylococcus infection; systematic review; treatment outcome; vancomycin intermediate Staphylococcus aureus infection |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。